NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.

Autor: O'Brien CF; Neurocrine Biosciences, San Diego, California, USA., Jimenez R; Neurocrine Biosciences, San Diego, California, USA., Hauser RA; University of South Florida, Tampa, Florida, USA., Factor SA; Emory University, Atlanta, Georgia, USA., Burke J; Neurocrine Biosciences, San Diego, California, USA., Mandri D; Biscayne Bay Institute, Miami, Florida, USA., Castro-Gayol JC; Research in Miami, Miami, Florida, USA.

Publikováno v: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2015 Oct; Vol. 30 (12), pp. 1681-7. Date of Electronic Publication: 2015 Sep 08.